Cancer Research and Treatment · 2009 · 50 citations · 9 references
MedicineNeurologyOncologyCancer Drug Toxicity ManagementChemotherapyNeuro-oncologySeizure DisordersSeizure ManagementClonic SeizuresGallbladder Cancer PharmacotherapyImaging Of SeizuresPhenytoin TherapyRadiologic ImagingSeizure PathophysiologySeizuresToxic Encephalopathy
A 58-year-old female receiving gemcitabine and cisplatin chemotherapy for stage IV gallbladder cancer developed the clinicoradiologic syndrome, posterior reversible encephalopathy syndrome (PRES). Just before the 4th gemcitabine chemotherapy cycle, she was admitted to the hospital with complaints of headache, dizziness, and generalized tonic-clonic seizures. A MRI was performed on the day when the seizure developed, and the findings showed patchy cortical and subcortical T2 hyperintensity without enhancement that involved both occipital and parietal lobes. Phenytoin loading and maintenance was started for prevention of recurrent seizures, which was successful. The follow-up brain MRI obtained 10 days after the seizure attack showed completely resolved radiologic findings. After the MRI findings revealed complete resolution, phenytoin maintenance was stopped. Even with discontinuation of phenytoin, she had no seizures or other clinical manifestations.
9
A Reversible Posterior Leukoencephalopathy Syndrome
Judy Hinchey, Claudia Chaves, B A Appignani et al. · New England Journal of Medicine · 1996 · 3.3K citations
Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.
Yasuhiro Ito, Yutaka Arahata, Yoji Goto et al. · PubMed · 1998 · 197 citations · Full text
5-Fluorouracil-induced leukoencephalopathy in patients with breast cancer
Sung Min Choi, Seung‐Han Lee, Yong Seok Yang et al. · Journal of Korean Medical Science · 2001 · 75 citations · Full text